Astrazeneca annual asset turnover
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Asset Turnover Growth & History (AZN)
Astrazeneca's asset turnover was 0.54 for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual asset turnover history
| Fiscal year | Period ended | Asset turnover | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.54 | 0.01 | +2.18% |
| 2024 | 2024-12-31 | 0.53 | 0.06 | +13.69% |
| 2023 | 2023-12-31 | 0.46 | 0.02 | +5.51% |
| 2022 | 2022-12-31 | 0.44 | 0.00 | +1.06% |
| 2021 | 2021-12-31 | 0.43 | 0.02 | +4.65% |
| 2020 | 2020-12-31 | 0.42 | 0.02 | +3.98% |
| 2019 | 2019-12-31 | 0.40 | 0.04 | +12.17% |
| 2018 | 2018-12-31 | 0.36 | −0.00 | −0.18% |
| 2017 | 2017-12-31 | 0.36 | −0.02 | −4.89% |
| 2016 | 2016-12-31 | 0.38 | — | — |
Astrazeneca quarterly asset turnover
Q4.19
Q2.20
Q4.20
Q2.21
Q1.26
Q2.26
| Fiscal quarter | Period ended | Asset turnover | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.54 | — | — |
| Q1 2026 | 2026-03-31 | 0.55 | — | — |
| Q2 2021 | 2021-06-30 | 0.43 | 0.02 | +3.96% |
| Q4 2020 | 2020-12-31 | 0.41 | 0.03 | +8.04% |
| Q2 2020 | 2020-06-30 | 0.41 | — | — |
| Q4 2019 | 2019-12-31 | 0.38 | — | — |
Astrazeneca asset turnover trends
Over the last five fiscal years, Astrazeneca's asset turnover increased from 0.42 to 0.54, a change of 0.12. The latest reported quarter, Q2 2026, shows 0.54.
About the metric
What asset turnover means
Asset turnover measures how much revenue a company generates for each unit of assets employed in the business. A higher ratio generally indicates more efficient asset use, although useful comparisons depend heavily on the industry.
Calculation and source
How asset turnover is calculated
TickerStat calculates annual asset turnover as reported revenue divided by average total assets. Quarterly values use trailing-12-month revenue and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...